Douglas Braun, PharmD, CSP, RPh

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

Bispecific antibodies amivantamab and tarlatamab hold promise for patients.

Data presented show significant advancements in treatment options.

Significant study results could inform clinical practice strategies.

Presentations detail clinical trial results and focus on drugs in the pipeline.

These study results may inform clinical practice strategies this year and beyond.

Significant study results may help inform clinical practice strategies.

Developments may soon impact clinical practice in hematology and oncology.